Company intelligence / Profile preview

Breakpoint Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Breakpoint Therapeutics has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential. The compound has shown in vivo efficacy in relevant cancer models when combined with standard of care PARP inhibitors, without adding toxicity or detrimental side effects on normal cells.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Evotec SE

Beyond the preview

Go deeper on Breakpoint Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Breakpoint Therapeutics.

Explore the full profile